Vericel Backtesting

Vericel Corporation -- USA Stock  

USD 4.6  0.1  2.13%

With this equity back-testing module your can estimate the performance of a buy and hold strategy of Vericel Corporation and determine expected loss or profit from investing in Vericel over given investment horizon. Also please take a look at Vericel Hype Analysis, Vericel Correlation, Vericel Valuation, Vericel Volatility as well as analyze Vericel Alpha and Beta and Vericel Performance
Investment Horizon     30 Days    Login   to change

Vericel 'What if' Analysis

September 18, 2017
No Change 0.00  0.0%
In 31 days
October 18, 2017
If you would invest  0.00  in Vericel on September 18, 2017 and sell it all today you would earn a total of 0.00 from holding Vericel Corporation or generate 0.0% return on investment in Vericel over 30 days. Vericel is related to or competes with NantKwest, Del Mar, Dimension Therapeutics, VBI Vaccines, Vascular Biogenics, and . It markets two autologous cell therapy products including Carticel an autologous chondrocyte implant for the treatment o...

Vericel Upside/Downside Indicators


Vericel Market Premium Indicators

Vericel lagged returns against current returns

 Current and Lagged Values 

Vericel regressed lagged prices vs. current prices

 Current vs Lagged Prices 

Vericel Backtested Returns

Macroaxis considers Vericel to be unusually risky. Vericel owns Efficiency Ratio (i.e. Sharpe Ratio) of -0.025 which indicates Vericel had -0.025% of return per unit of risk over the last 1 month. Macroaxis philosophy towards measuring risk of any stock is to look at both systematic and un-systematic factors of the business, including all available market data and technical indicators. Vericel Corporation exposes twenty-one different technical indicators which can help you to evaluate volatility that cannot be diversified away. Please be advised to validate Vericel Coefficient Of Variation of (3,911) and Risk Adjusted Performance of 0.0037 to confirm risk estimate we provide. Macroaxis gives Vericel performance score of 0 on a scale of 0 to 100. The entity has beta of -1.0943 which indicates . Even though it is essential to pay attention to Vericel current price movements, it is always good to be careful when utilizing equity historical returns. Macroaxis philosophy towards measuring future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Vericel Corporation exposes twenty-one different technical indicators which can help you to evaluate its performance. Vericel has expected return of -0.12%. Please be advised to validate Vericel Jensen Alpha, Potential Upside as well as the relationship between Potential Upside and Skewness to decide if Vericel past performance will be repeated at some point in the near future.
Advice Volatility Trend Exposure Correlations
15 days auto-correlation(0.53) 

Good reverse predictability

Vericel Corporation has good reverse predictability. Overlapping area represents the amount of predictability between Vericel time series from September 18, 2017 to October 3, 2017 and October 3, 2017 to October 18, 2017. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Vericel price movement. The serial correlation of -0.53 indicates that about 53.0% of current Vericel price fluctuation can be explain by its past prices. Given that Vericel Corporation has negative autocorrelation for selected time horizon, investors may consider taking a contrarian position regarding future price movement of Vericel for similar time interval.
Correlation Coefficient -0.53
Spearman Rank Test -0.61
Price Variance 0.22
Lagged Price Variance 0.21

Vericel Lagged Returns

 Regressed Prices 

Vericel Performance vs DOW

The median price of Vericel for the period between Mon, Sep 18, 2017 and Wed, Oct 18, 2017 is 4.95 with a coefficient of variation of 9.14. The daily time series for the period is distributed with a sample standard deviation of 0.47, arithmetic mean of 5.12, and mean deviation of 0.39. The Stock did not receive any noticable media coverage during the period.
Price Growth (%)